NVSEF
NOVARTIS AG
Next earnings Jul 21, 2026 · consensus $2.17 EPS, $14.5B rev
$158.24
▲ +3.17%$158.24▲ +36.01%
over 1Y
L $107.99H $166.07
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+3.2%
1W+3.5%
1M+9.8%
3M+2.2%
YTD+15.3%
1Y+36.0%
Sell
Conviction
Horizon
Medium (3–12mo)
Street · 34 analysts
Buy
Mixed signals in the latest filings.
NOVARTIS AG shows limited reported revenue.
On these fundamentals, NVSEF screens as SELL on the SEC figures.
Is NVSEF a buy? The one-page verdict, explained →
The options angle
model · matches our verdictBear put spread~60d expiry
- Long put 158 @ ~7.01 est
- Short put 142 @ ~1.68 est
debit $533max +$1,067max −$533BE 152.67
SELL verdict, defined risk: profits into weakness down to the short strike; max loss is the net debit.
Educational template, not a trade recommendation. Strikes and premiums are Black-Scholes model estimates from the last close and 30-day realized volatility — real chains, spreads and IV will differ. Options involve substantial risk.
Financials · annual, by fiscal year
No income data filed.
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$293B
EV / EBITDA—
EV / Sales—
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield—
FCF yield—
Quality & risk
ROIC (est.)—
Free cash flow—
Total debt—
Net cash—
Capital returns
Buyback yield—
Dividend yield (est.)—
Shareholder yield—
Shares Δ YoY-3.4%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Recent filings
all on EDGAR ↗6-KPeriod ending 2026-06-112026-06-11open ↗144Filing2026-04-30open ↗6-KPeriod ending 2026-03-312026-04-28open ↗6-KPeriod ending 2026-03-182026-03-18open ↗424B5Filing2026-03-17open ↗FWPFiling2026-03-17open ↗424B5Filing2026-03-16open ↗144Filing2026-02-12open ↗144Filing2026-02-09open ↗S-8Filing2026-02-04open ↗6-KPeriod ending 2025-12-312026-02-04open ↗6-KPeriod ending 2025-12-312026-02-04open ↗
Frequently asked
- Is NOVARTIS AG (NVSEF) a buy?
- NVSEF currently carries a Sell rating with 2/5 conviction, derived from its latest SEC filings. Mixed signals in the latest filings.
Sources: SEC EDGAR (CIK 0001114448, latest 6-K filed 2026-06-11) · EODHD · as of 6/20/2026, 7:19:19 AM.
About this recommendation — produced by TENK/calls (tenkcalls.com), Luxembourg · not investment advice
Rule-based analysis, generated automatically from SEC filing data.
Investment recommendation produced by TENK/calls (tenkcalls.com), Luxembourg. Completed Jun 20, 2026, 3:19 AM ET. Ratings & methodology: definitions · All recommendations to date: track record · Conflicts: disclosures. Not investment advice.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.